Allied Market Research


White Fungus Market

White Fungus Market Size, Share, Competitive Landscape and Trend Analysis Report, by Drug Type, by Route of Administration and, by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Therapeutics

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

White Fungus Market Overview 2030:

White fungus is a fungal infection that occurs majorly among immunocompromised people, which includes COVID-19 positive patients, those with uncontrolled diabetes, people on a high dose of steroids, cancer, and AIDS. If the infection reaches the digestive tract, an individual can face difficulty in eating and swallowing food. If the infection is inside head or skull, the symptoms are headache and nausea. Some of the common symptoms are white patches on skin, white tongue, diarrhea, and hypoxia (low oxygen saturation levels), even after recovery from COVID-19.

It is not confirmed that which fungi is causing this disease; some of the doctors say that it is drug-resistant candidiasis. Spores of this fungus are present in the soil and air but it is noninfectious as our immunity suppresses the effect of fungi. Use of unhygienic mask and tap water used in humidifier attached to oxygen increases the spore accumulation in the body, which further gets worse due to suppressed immunity caused by the use of steroids in COVID-19 therapy. Major reason for spread of this infection is unknown and researchers are still working to find out the source of this disease.

COVID-19 Impact Analysis

  • COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
  • Coronavirus disease 2019 (COVID-19) has created an economic crisis in addition to the healthcare crisis. The pandemic has stretched healthcare system worldwide; developed countries are expected to cause economic recession. The pandemic had an adverse impact on the healthcare system, resulting in 50% to 70% drop in revenue from March. Many small hospitals, clinics, and nursing homes have been forced to shut their operations. In addition, social distancing and localized curfews have resulted in delayed elective surgical procedures. Further, visa cancellations have led to an interruption in medical tourism and can negatively impact the healthcare services market growth.
  • COVID-19 has given rise to many post COVID complications, which includes white fungus disease. Due to low immunity and improper hygiene, there are chances of developing white fungus infection. Due to sudden outbreak, majority of companies have started research for the treatment of this disease.
  • White fungus can damage organs if not treated in time, so production of antifungal medication has gradually increased in pharma companies as the demand for the white fungus medication increased. The COVID-19 patients who recovered by taking steroids are witnessing low immunity, due to which they are getting infected easily.
  • This demand for antifungal agents has presented huge opportunity for the manufacturers of white fungus management drugs, as many developing countries are facing shortage of these drugs. Thus, the pharmaceutical and API Industry is expected to witness significant growth, owing to increase in demand for white fungus medication.

Top Impacting Factors

  • Rise in incidences of white fungus cases after recovery from COVID-19 patients who have diabetes, cancer, and other co-morbidities has increased the demand for white fungus medications. There is gradual increase in investment in the R&D sector of pharmaceutical industry due to white fungus.
  • Increase in the number of COVID-19 cases is the key driving factor of the white fungus market.
  • However, high prices of the medication are likely to restrain the white fungus market. The rapid increase of the disease and fatal results serves as an opportunity for the market.
  • Decrease in immunity of patients due to various treatments including treatment for COVID-19 is expected to provide opportunity to the white fungus market in countries such as India, Brazil, Indonesia.

Market Trends

Increase in prevalence of white fungus after recovery or during treatment of COVID-19 infections has prompted manufacturers to develop advanced and formulated medication for better clinical results.Center for Disease Control and Prevention (CDC) estimated that around 1.7 million people will be hospitalized for post COVID-19 complication. High prevalence of post COVID-19 complications is giving rise to new infections such as white fungus, which is propelling players to invest in R&D.

Manufacturers are focusing on advanced formulations with novel drug delivery systems such as nanotechnology. Use of advanced nanotechnology system for treatment in white fungus is emerging as one of the critical factors behind the growth of market.

Pfizer, Inc. is currently conducting clinical trials for determining the effectiveness, safety, and treatment patterns of Isavuconazole sulfate in the treatment of patients suffering from mucormycosis or invasive aspergillosis and white fungus. The trial is currently in Phase II and is expected to be completed by May 26, 2022.

Key Benefits of Report

  • This report presents the detailed analysis of the white fungus market along with current trends, opportunities, and future estimates for the investments in market.
  • The report presents information related to the key drivers, restraints, and new technological development in the white fungus market.
  • The current market is analyzed to emphasize the white fungus market.
  • Porter’s five forces analysis illustrate the potency of buyers and suppliers in market.
  • The report provides detailed analysis of the white fungus market based on market competition and how it will take shape in upcoming years.

Questions Answered in the White Fungus Market Report

  • What is white fungus?
  • What are the causes of white fungus disease?
  • What are the driving factors, restraints, and opportunities of the white fungus market?
  • Which are the leading players in the white fungus market?
  • What future projections will help in taking strategic steps in the future?
  • Which are the major end user sectors in white fungus market?
  • What is the major regional market in white fungus market?
  • What are the key benefits of this white fungus market report?

White Fungus Market Report Highlights

Aspects Details
By Drug Type
  • Azoles
    • Fluconazole
    • Itraconazole
  • Echinocandins
    • Caspofungin
  • Polyene
    • Amphotericin B
By Route of Administration
  • Oral
  • Topical
  • Parenteral
By End User
  • Pharmacies
  • Hospitals
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Astellas Pharma Inc, Pfizer Inc., Glenmark Pharmaceuticals Ltd, Novartis, Merck and Co. Inc., Sigma-Aldrich Corporation, Sanofi-Aventis, Bayer Healthcare, GlaxoSmithKline, Abbott Laboratories

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

White Fungus Market

Global Opportunity Analysis and Industry Forecast, 2023-2032